Clinical Trials
9 trialsNCT01787500 2026-04-23
Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery
M.D. Anderson Cancer Center
Phase 1 Completed
NCT05768178 2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3 Recruiting
NCT06603376 2024-09-19
Irinotecan Hydrochloride Liposome Injection (â…¡) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated Advanced Colorectal Cancer
Shanghai Changzheng Hospital
Phase 2 Recruiting
NCT02291289 2024-05-06
MODUL
Hoffmann-La Roche
Phase 2 Completed
NCT05233332 2023-05-31
mCRC
Shanghai Kechow Pharma, Inc.
Phase 2 Unknown
NCT03727763 2021-08-19
Cetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT)
Shanghai Changzheng Hospital
Phase 2 Unknown
NCT02164916 2020-12-30
S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer
SWOG Cancer Research Network
Phase 2 Completed
NCT00405587 2017-08-22
Safety Study of PLX4032 in Patients With Solid Tumors
Plexxikon
Phase 1 Completed
NCT01791309 2016-01-05
Vemurafenib and Panitumumab Combination Therapy in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed